StockData
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc. (CASIF) shareholders

CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 1/30
$0.10+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 21M shares
Institutional holders
1
1 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
WEI-WU HE, Ph.D.
Joint filing with Emerging Technology Partners, LLC (52.00%), ETP Global III Fund L.P. (49.30%)
23,985,53558.80%13D (active) amendmentMay 18, 2026
James Huang
Joint filing with Panacea Venture Healthcare Fund II, L.P. (22.00%), Panacea Venture Healthcare Fund II GP Company, Ltd. (22.00%) and 1 more
4,651,52722.50%13D (active) amendmentDec 16, 2025
Chen Zhenfeng2,255,63611.00%13G (passive)Sep 30, 2025
Venrock Healthcare Capital Partners III, L.P.
Joint filing with VHCP Co-Investment Holdings III, LLC (9.20%), Venrock Healthcare Capital Partners EG, L.P. (9.20%) and 4 more
1,987,2599.20%13G (passive) amendmentDec 31, 2025
Jingbo Wang
Joint filing with Kuiguang Niu (5.00%), Snow Moon Ltd (5.00%) and 9 more
1,019,8525.00%13D (active) amendmentSep 30, 2025
Quan Zhou
Joint filing with IDG-Accel China Growth Fund III L.P. (5.90%), IDG-Accel China III Investors L.P. (5.90%) and 3 more
992,6386.40%13D (active) amendmentDec 30, 2024
Foresite Capital Management VI, LLC
Joint filing with Foresite Capital Fund VI, L.P. (5.10%), James Tananbaum (5.10%)
787,1215.10%13G (passive) amendmentJun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CASIFValueChange% of portfolio
West Paces Advisors Inc.1000.00%$17New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610M0.0%1 / 00 / 10M0M
Q1 202610M0.0%0 / 10 / 150M1M
Q4 2025161M6.1%1 / 26 / 70M1M
Q3 2025223M12.7%3 / 53 / 50M0M
Q2 2025242M11.0%3 / 48 / 20M1M
Q1 2025233M13.4%3 / 52 / 20M0M
Q4 2024223M12.9%4 / 27 / 21M0M
Q3 2024201M6.4%3 / 42 / 51M0M
Q2 2024230M1.7%7 / 25 / 40M0M
Q1 2024200M1.2%6 / 51 / 40M0M
Q4 2023180M1.3%3 / 35 / 40M0M
Q3 2023190M1.7%2 / 37 / 20M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Wei R. GaoGeneral Counsel––Apr 16, 2026
Kun QianGlobal Controller––Apr 13, 2026
Hai HuangGlobal Chief Commercial Ofcr––Apr 7, 2026
Chunhua WangChief Operating Officer––Apr 3, 2026
Alexander A. ZukiwskiGlobal Chief Medical Officer––Apr 3, 2026
Thomas FolinsbeeDirector––Apr 23, 2026
Xuebo ZengDirector––Apr 20, 2026
Barbara Helene Hannelore Krebs-PohlDirector––Mar 27, 2026
Alex WuDirector34,1680.17%Mar 25, 2026
James HuangDirector4,529,95622.04%Mar 18, 2026
Wei-Wu HeDirector, 10% owner2,592,30112.61%Mar 18, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
32.8
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 9 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CASI Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Panacea Innovation Ltd
Owner
Mar 15, 2024171,000$534.19KMar 15, 2024Open Market Purchase
Panacea Innovation Ltd
Owner
Mar 5, 2024134,000$925.94KMar 5, 2024Open Market Purchase

See a number that looks wrong?